Business
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-s...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceToronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.Dates: Tuesday April 21, 2026-Wednesday April 22, 2026Time:8:30 AM - 5:00 PM ETLocation:Metro Toronto Convention Centre, North Building255 Front St WToronto, OntarioM5V 2W6 Chris Seto, CEO will be speaking at 1030 AM ET ON Wednesday, April 22nd. Interested parties can register to attend the conference here. Members of Spectral Medical Inc. management will also be taking meetings from interested investors throughout the day. Take advantage of the opportunity and reach out to the team.To register for the conference, please follow this link. About Spectral Medical Inc.Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA™), the only clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In February 2020, the Company entered into an exclusive distribution agreement with Vantive (formerly Baxter) for the commercialization of PMX in the United States and Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study evaluating PMX in addition to standard care vs. standard care alone in patients with endotoxic septic shock, and...